Hepatitis B Surface Antigen Serum Level Is Correlated with Fibrosis Severity in Treatment-Naïve, Chronic Hepatitis B Patients in Côte d’Ivoire (West Africa)?

Abstract

HBsAg serum level (quantification) may be useful for managing hepatitis B virus (HBV) infection patients. However few studies especially in Africa have evaluated the association between HBsAg serum level and liver fibrosis severity. The objective of this study was to estimate the correlation between HBsAg serum level and liver fibrosis severity with treatment naive chronic hepatitis B patients in Cote d’Ivoire. Methodology: It is a prospective study covering from February 1st, 2014 to April 30st, 2015 at Centre Hospitalier et Universitaire de Yopougon and a private medical office in Abidjan, Cote d’Ivoire. Inclusion criteria for patients were: HBsAg positive, known HBeAg status, serum HBsAg levels, serum HBV DNA levels, complex serum markers and absence of HCV, HDV, or HIV co-infection, drinking more than 30 g/day for men and 20 g/day in women over 10 years, metabolic disease and/or hepatic overload. Pearson’s Chi-square test (r2), Anova, Spearman, T-Student, Pearson’s (r) correlations and Mann Withney’s Test were carried out as appropriate. A p value < 0.05 was taken as significant. Results: We recruited, 105 patients (77 men) of whom the medium age was 39.01 ± 9.72 years. Predominant hepatitis B viral genotype was E (93%). Less than 10% patients had an inactive HBV in HBeAg-negative. Patients had an average high HBsAg serum level (mean 12111.2 ± 10617.4 IU/ml) as well as the one viral load (mean 4.4 e7 ± 7.5 e7). Serum ALAT levels averaged at the upper limit of normal value. The average liver fibrosis score was 0.34 ± 0.22 and the degree of viral activity was 0.19 ± 0.20. Half of our patients had no fibrosis (35.24%) or had mild fibrosis (20.95%). No significant association was observed between HBsAg serum level and patient age (p = 0.3994), genre (p = 0.8075) or serum ALT levels (p = 0, 0787). In multivariate analysis, there’s a significant correlation (r = 0.239, p = 0.014) between HBV DNA levels and HBsAg serum level. There’s a significant correlation (r = 0.923, p < 0.0001) between HBsAg serum level and the dosage of alpha-fetoprotein. HBsAg serum level was not associated with the fibrosis stage (p = 0.281). HBsAg levels average with patients without fibrosis or carry a slight fibrosis (F0, F1) was higher than patients with moderate to severe fibrosis (F2, F3, F4): 13679.2 UI/ml ± 1956.48 versus 10610.52 UI/ml ± 8998.99 (p = 0.29). There’s a negative correlation between HBsAg level and the liver fibrosis score was negative (r = -0.069, p = 0.48). No significant association between HBsAg level and the liver fibrosis patients that were normal (p = 0.7965) or elevated (p = 0.5845). HBV DNA level was significantly associated with fibrosis score (r = 0.30, p = 0.0018). Conclusion: This study shows that there’s a negative correlation between HBsAg serum level and liver fibrosis severity treatment naive with African chronic hepatitis B viral HBeAg-negative patients.

Share and Cite:

Bathaix, M. , Soro, D. , Bangoura, A. , Doffou, A. , Koné, S. , Kissy, Y. , Kouamé, D. , Dé, A. , Alassane, M. , Alain, A. and Yoman, A. (2015) Hepatitis B Surface Antigen Serum Level Is Correlated with Fibrosis Severity in Treatment-Naïve, Chronic Hepatitis B Patients in Côte d’Ivoire (West Africa)?. Open Journal of Gastroenterology, 5, 164-172. doi: 10.4236/ojgas.2015.511026.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Yao Bathaix, M.F., Attia, K.A., Bagny, A., Bangoura, D.A., Mahassadi, K.A., Kouamé, D.H., Kissi-Anzouan, O., Diallo, K. and Ndri-Yoman, A.T. (2015) Niveau de connaisances des sages-femmes sur la prévention de la trans-mission mère-enfant du virus de l’hépatite B à Abidjan (Cote d’Ivoire). Journal Africain d’Hépato-Gastroentérologie, 9, 22-25.
[2] Attia, K.A., N’dri Yoman, A.T., Talla, P., Bathaix, Y., Mahassadi, A., et al. (2003) Facteurs prédictifs des signes endoscopiques d’hypertension portale sévère chez le cirrhotique en milieu Africain: A propos de 131 cas. Médecine d’Afrique Noire, 50, 109-114.
[3] Liang, L.-B., Zhu, X., Yan, L.-B., Du, L.-Y., Liu, C., Chen, L.-Y., et al. (2015) Serum Hepatitis B Surface Antigen Titer and Transient Elastography in Screening for Insignificant Fibrosis in HBeAg-Positive Chronic Hepatitis B Patients. Therapeutics and Clinical Risk Management, 11, 229-235.
[4] Anastasiou, J., Alisa, A., Virtue, S., Portmann, B., Murray-Lyon, I. and Williams, R. (2010) Non Invasive Markers of Fibrosis and Inflammation in Clinical Practice: Prospective Comparison with Liver Biopsy. European Journal of Gastroenterology & Hepatology, 22, 474-478.
http://dx.doi.org/10.1097/MEG.0b013e328332dd0a
[5] Martinot-Peignoux, M., Carvalho-Filho, R., Lapalus, M., Netto-Cardoso, A.C.F., et al. (2013) Hepatitis B Surface Antigen Serum Level Is Associated with Fibrosis Severity in Treatment-Naive, e Antigen-Positive Patients. Journal of Hepatology, 58, 1089-1095.
http://dx.doi.org/10.1016/j.jhep.2013.01.028
[6] Wang, H., Yan, R., Zhou, Y., Wang, M.S., Ruo, G.Q. and Cheng, M.J. (2014) Comparison of Hepatitis B Surface Antigen and e Antigen in Predicting Liver Histology in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. Hepatology International, 8, 216-223.
http://dx.doi.org/10.1007/s12072-013-9502-8
[7] Tan, Z., Lia, M., Kuang, X., Tang, Y., Fan, Y., Deng, G., Wang, Y. and He, D. (2014) Clinical Implications of Hepatitis B Surface Antigen Quantitation in Thenatural History of Chronic Hepatitis B Virus Infection. Journal of Clinical Virology, 59, 228-234.
http://dx.doi.org/10.1016/j.jcv.2014.01.013
[8] Liaw, Y.-F. (2009) Hepatitis B Infection. Lancet, 373, 582-592.
http://dx.doi.org/10.1016/S0140-6736(09)60207-5
[9] Jaroszewicz, J., Calle Serrano, B., Wursthorn, K., Deterding, K., Schlue, J., Raupach, R., et al. (2010) Hepatitis B Surface Antigen (HBsAg) Levels in the Natural History of Hepatitis B Virus (HBV)-Infection: A European Perspective. Journal of Hepatology, 52, 514-522.
http://dx.doi.org/10.1016/j.jhep.2010.01.014
[10] Nguyen, T., Thompson, A.J., Bowden, S., Croagh, C., Bell, S., Desmond, P.V., et al. (2010) Hepatitis B Surface Antigen Levels during the Natural History of Chronic Hepatitis B: A Perspective on Asia. Journal of Hepatology, 52, 508-513.
http://dx.doi.org/10.1016/j.jhep.2010.01.007
[11] Brunetto, M.R., Oliveri, F., Colombatto, P., Moriconi, F., Ciccorossi, P., Coco, B., et al. (2010) Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active from Inactive Hepatitis B Virus Genotype D Carriers. Gastroenterology, 139, 483-490.
http://dx.doi.org/10.1053/j.gastro.2010.04.052
[12] Liaw, Y.-F. (2011) Clinical Utility of Hepatitis B Surface Antigen Quantification in Patients with Chronic Hepatitis B: A Review. Hepatology, 54, 1-9.
http://dx.doi.org/10.1002/hep.24473
[13] Brunetto, M.R., Moriconi, F., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., et al. (2009) Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to Peginterferon Alfa-2a in HBeAg-Negative Chronic Hepatitis B. Hepatology, 49, 1141-1150.
http://dx.doi.org/10.1002/hep.22760
[14] Moucari, R., Mackiewicz, V., Lada, O., Ripault, M.P., Castelnau, C., Martinot-Peignoux, M., et al. (2009) Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients. Hepatology, 49, 1151-1157.
http://dx.doi.org/10.1002/hep.22744
[15] Chan, H.L. (2012) Identifying Hepatitis B Carriers at Low Risk for Hepatocellular Carcinoma. Gastroenterology, 142, 1057-1060.
http://dx.doi.org/10.1053/j.gastro.2012.03.013
[16] Tseng, T.C., Liu, C.J., Yang, H.C., Su, T.H., Wang, C.C., Chen, C.L., et al. (2012) High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients with Low HBV Load. Gastroenterology, 142, 1140- 1149.
http://dx.doi.org/10.1053/j.gastro.2012.02.007
[17] Chan, H.L., Tse, C.H., Mo, F., Koh, J., Wong, V.W., Wong, G.L., et al. (2010) High Viral Load and Hepatitis B Virus Subgenotype C Are Associated with Increased Risk of Hepatocellular Carcinoma. Journal of Clinical Oncology, 26, 177-182.
http://dx.doi.org/10.1200/JCO.2007.13.2043
[18] Chen, C.J., Yang, H.I., Su, J., Jen, C.L., You, S.L., Lu, S.N., et al. (2006) Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DVA Level. JAMA, 295, 65-73.
http://dx.doi.org/10.1001/jama.295.1.65
[19] Seto, W.K., Wong, D.K., Fung, J., Ip, P.P., Yuen, J.C., Hung, I.F., et al. (2012) High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B. PLoS ONE, 7, e43087.
http://dx.doi.org/10.1371/journal.pone.0043087
[20] Kra, O., N’Dri, N., Ehui, E., Ouattara, B. and Bissagnene, E. (2007) Prévalence de l’antigène HBs chez les donneurs de sang au centre régional de transfusion sanguine de Bouake (Cote d’ivoire) en 2001. Bulletin de la Société de pathologie exotique, 100, 127-129.
[21] Sombié, R., Bougouma, A., Diallo, O., Bonkoungou, G., Cissé, R., Sangare, L., et al. (2010) Hépatite B chronique: Aspects épidémiologique, diagnostique, thérapeutique et évolutif au centre hospitalier universitaire Yalgado Ouédraogo de Ouagadougou. Journal Africain d’Hépato-Gastroentérologie, 4, 3-10.
http://dx.doi.org/10.1007/s12157-009-0137-2
[22] Kodjo, N., Latoundji, S.B.I., Kposso, A.R., Saké, A.K., Vignon, R.K., Houinato, D., et al. (2014) Connaissances et croyances en matière d’hépatite virale B et C en république du Benin. Journal Africain d’Hépato-Gastroentérologie, 9, 2-6.
[23] Creach, M.-A. (2009) Aspects épidémiologiques et cliniques du portage chronique de l’antigène HBs dans les unités militaires des régions Nord-Est de la France. Thèse, Universtié de Nancy, Nancy, 82 p.
[24] Hadziyannis, S.J. (2011) Natural History of Chronic Hepatitis B in Euro-Mediterranean and African Countries. Journal of Hepatology, 55, 183-191.
http://dx.doi.org/10.1016/j.jhep.2010.12.030
[25] Mulders, M.N., Venard, V.N., Jayou, M., et al. (2004) Low Genetic Diversity despite Hyperendemicity of Hepatitis B Virus Genotype E throughout West Africa. The Journal of Infectious Diseases, 190, 400-408.
http://dx.doi.org/10.1086/421502
[26] Brunetto, M.R. (2010) A New Role for an Old Marker, HBsAg. Journal of Hepatology, 52, 475-477.
http://dx.doi.org/10.1016/j.jhep.2009.12.020
[27] Hadziyannis, S.J. and Papatheodoridis, G.V. (2006) Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment. Seminars in Liver Disease, 26, 130-141.
http://dx.doi.org/10.1055/s-2006-939751
[28] Ganji, A., Esmaeilzadeh, A., Ghafarzadegan, K., Helalat, H., Rafatpanah, H. and Mokhtarifar, A. (2011) Correlation between HBsAg Quantitative Assay Results and HBV DNA Levels in Chronic HBV. Hepatitis Monthly, 11, 342-345.
[29] Thompson, A.J., Nguyen, T., Iser, D., Ayres, A., Jackson, K., Littlejohn, M., et al. (2010) Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Titers: Disease Phase Influences Correlation with Viral Load and Intrahepatic Hepatitis B Virus Markers. Hepatology, 51, 1933-1944.
http://dx.doi.org/10.1002/hep.23571
[30] Iloeje, U.H., Yang, H.I., Jen, C.L., Su, J., Wang, L.Y., You, S.L., et al. (2007) Risk and Predictors of Mortality Associated with Chronic Hepatitis B Infection. Clinical Gastroenterology and Hepatology, 5, 921-931.
http://dx.doi.org/10.1016/j.cgh.2007.06.015
[31] Jang, J.W., Yoo, S.H., Kwon, J.H., You, C.R., Lee, S., Lee, J.H., et al. (2011) Serum Hepatitis B Surface Antigen Levels in the Natural History of Chronic Hepatitis B Infection. Alimentary Pharmacology & Therapeutics, 34, 1337-1346.
http://dx.doi.org/10.1111/j.1365-2036.2011.04888.x

Journals Menu
Follow SCIRP
Contact us
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.